首页> 外文期刊>DNA and Cell Biology >Identification of SARS-CoV-2 Proteins Binding Human mRNAs As a Novel Signature Predicting Overall Survival in Hepatocellular Carcinoma
【24h】

Identification of SARS-CoV-2 Proteins Binding Human mRNAs As a Novel Signature Predicting Overall Survival in Hepatocellular Carcinoma

机译:鉴定SARS-COV-2蛋白结合人MRNA作为预测肝细胞癌整体存活的新签名

获取原文
获取原文并翻译 | 示例
           

摘要

The impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is the virus causing coronavirus disease 2019 (COVID-19), has been confirmed in cancers through binding specific mRNAs to invade human cells. Therefore, the aim of this study described here was to develop and validate novel SARS-CoV-2 proteins binding human mRNAs (SPBRs) signature to predict overall survival (OS) in hepatocellular carcinoma (HCC). Using multivariate Cox regression analysis, a set of SPBRs was identified to establish a multigene signature in the Cancer Genome Atlas repositories cohort. Furthermore, a nomogram was established based on the signature and clinical risk factors to improve risk stratification for individual patients. External validation was performed in the International Cancer Genome Consortium (ICGC) cohort. A six-SPBR signature was built to classify patients into two risk groups using a risk score with different OS in two cohorts (all p < 0.0001). Multivariate regression analysis demonstrated the signature was an independent predictor of HCC. Moreover, the signature presented an excellent diagnostic power in differentiating HCC and normal tissues. Gene set enrichment analysis demonstrated that high-risk group was closely enriched in cell cycle, DNA replication, microRNAs in cancer, and cytokine-cytokine receptor interaction. The novel signature demonstrated great clinical value in predicting the OS for patients with HCC, and will provide a good reference between cancer research and SARS-CoV-2 and help individualized treatment in HCC.
机译:严重急性呼吸综合征冠状病毒2(SARS-CoV-2)是导致2019年冠状病毒病(COVID-19)的病毒,其影响已通过结合特异性mRNAs入侵人类细胞在癌症中得到证实。因此,本研究的目的是开发和验证新的SARS-CoV-2蛋白结合人类mRNAs(SPBRs)信号,以预测肝细胞癌(HCC)的总生存率(OS)。使用多变量Cox回归分析,确定了一组SPBR,以在癌症基因组图谱库队列中建立多基因标记。此外,根据特征和临床风险因素建立列线图,以改善个体患者的风险分层。外部验证在国际癌症基因组联盟(ICGC)队列中进行。使用两个队列中不同OS的风险评分将患者分为两个风险组(均p<0.0001)。多元回归分析表明,该特征是HCC的独立预测因子。此外,该特征在区分HCC和正常组织方面具有极好的诊断能力。基因集富集分析表明,高危人群在细胞周期、DNA复制、癌症中的microRNA和细胞因子-细胞因子受体相互作用方面密切富集。这一新的特征在预测肝癌患者的OS方面具有重要的临床价值,将为癌症研究和SARS-CoV-2之间提供良好的参考,并有助于肝癌的个体化治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号